A Phase 2, Non-inferiority, Open-label, Randomized Controlled Study to Evaluate the Immunogenicity and Safety of Comvigen (Bivalent) Vaccine as a Booster Dose in Adults Who Have Received a Previous Booster Dose of an Approved COVID-19 Vaccine
Latest Information Update: 23 Oct 2023
At a glance
- Drugs ChulaCov19 mRNA vaccine-Chulalongkorn University (Primary) ; BNT 162a1
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- 17 Oct 2023 Status changed from not yet recruiting to recruiting.
- 07 Jul 2023 New trial record